## Abstract

Objective: The German Infant Nutritional Intervention (GINI) trial, a prospective, randomized, double-blind intervention, enrolled children with a hereditary risk for atopy. When fed with certain hydrolyzed formulas for the first 4months of life, the risk was reduced by 26-45% in PP and 8-29% in intention-to-treat (ITT) analyses compared with children fed with regular cow's milk at age 6. The objective was to assess the cost-effectiveness of feeding hydrolyzed formulas. Patients and Methods: Cost-effectiveness was assessed with a decision tree model programmed in TreeAge. Costs and effects over a 6-yr period were analyzed from the perspective of the German statutory health insurance (SHI) and a societal perspective at a 3% effective discount rate followed by sensitivity analyses. Results: The extensively hydrolyzed casein formula would be the most cost-saving strategy with savings of 478€ per child treated in the ITT analysis (CI95%: 12€; 852€) and 979€ in the PP analysis (95%CI: 355€; 1455€) from a societal perspective. If prevented cases are considered, the partially whey hydrolyzed formula is cost-saving (ITT -5404€, PP -6358€). From an SHI perspective, the partially whey hydrolyzed formula is cost-effective, but may also be cost-saving depending on the scenario. An extensively hydrolyzed whey formula also included into the analysis was dominated in all analyses. Conclusions: For the prevention of AE, two formulas can be cost-effective or even cost-saving. We recommend that SHI should reimburse formula feeding or at least the difference between costs for cow's milk formula and the most cost-effective formula.

Original language | English |
---|---|

Pages (from-to) | 597-604 |

Number of pages | 8 |

Journal | Pediatric Allergy and Immunology |

Volume | 23 |

Issue number | 6 |

DOIs | |

State | Published - Sep 2012 |

## Keywords

- Atopic dermatitis
- Atopic eczema
- Cost-effectiveness analysis
- Hydrolyzed formula
- Nutrition
- Prevention